[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yong Wha Moon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100642597","to-evaluate-the-safety-of-autologous-tumor-infiltrating-lymphocytestils-for-the-treatment-of-recurrent-ovarian-cancer-100642597",false,"NCT07651124","To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer","A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Recurrent ovarian cancer\n* There is a cancerous lesion that can be removed by biopsy or surgery.\n\nExclusion Criteria:\n\n* Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy\n* Patient deemed unsuitable by the principal investigator","FEMALE","20 Years",{"count":19,"type":20},6,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.\n\nParticipants undergo the following process:\n\nThere must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject.\n\nThese are processed into human cells for administration and injected into the subject.",[26],"Recurrent Ovarian Cancer","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-16","ACTUAL",{"date":33,"type":31},"2025-04-01",{"date":35,"type":20},"2027-06-30",{"name":37,"class":38},"Yong Wha Moon","OTHER",""]